亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

尼美舒利

 
 
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
過期 長期有效
更新 2011-04-16 11:44
 

武漢遠城科技發展有限公司銷售八部

企業會員第16年
資料未認證
保證金未繳納
詳細說明
尼美舒利
英文名稱:nimesulide
中文別名:N-(4-硝基-2-苯氧基)甲基磺酰胺;  
外觀:黃色或淡黃色結晶粉末.無臭無味
含 量:(HPLC): ≥99.5%
CAS 號:51803-78-2  
分子式:C13H12N2O5S 
分子量:308.30  
產品用途 :尼美舒利有很強的解熱、鎮痛和抗炎作用;
口服解熱作用比對乙酰氨基酚強200倍;鎮痛作用比阿司匹林強24倍。
此外,還具有抗過敏作用、
抗血小板聚集作用和抑制金屬蛋白酶合成作用。臨床用于風濕性關節炎、
骨關節炎、術后疼痛、軟組織損傷等。“阿司匹林哮喘”者可使用尼美舒利。
nimesulide
Chinese Alias: N-(4 - nitro -2-- phenoxy) methyl-sulfonamide;
Appearance: yellow or light yellow crystalline powder. Odorless
Purity: (HPLC): ≥ 99.5%
CAS No. :51803-78-2
Molecular formula: C13H12N2O5S
MW: 308.30
Packing: 25kg cardboard drum
Usage: Nimesulide has a strong antipyretic, analgesic and
 anti-inflammatory effects; oral antipyretic effects of 
acetaminophen than 200 times more powerful; analgesic effect
 24 times stronger than aspirin. In addition, it also has 
anti-allergic effects,
Anti-platelet aggregation and inhibition of MMP synthesis. 
Clinic for rheumatoid arthritis, osteoarthritis, postoperative
 pain, soft tissue injury. "Aspirin asthma" may use nimesulide.

 

舉報收藏 0評論 0
更多>本企業其它產品
氯唑沙宗 羅非昔布 美羅培南 美洛昔康 美索巴莫 帕馬溴 潑尼松龍
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |